CATX Perspective Therapeutics Inc

Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.

Truist Securities BioPharma SymposiumDate: November 7, 2024Location: Lotte New York Palace - New York, NYFormat: 1x1 meetings only

UBS Global Healthcare ConferenceDate: November 13, 2024Location: Rancho Palos Verdes, CAFormat: Fireside ChatTime: 2:45 p.m. – 3:20 p.m. PT / 5:45 p.m. – 6:20 p.m. ET

Stifel 2024 Healthcare ConferenceDate: November 18, 2024Location: New York, NYFormat: Fireside ChatTime: 9:10 a.m. – 9:40 a.m. ET

Jefferies London Healthcare ConferenceDate: November 19-21, 2024Location: London, UKFormat: 1x1 meetings only

Webcast events can be accessed live, and replays will be archived for 90 days and available through the Investors page on the Perspective website at https://perspectivetherapeutics.com/investor-center.

About Perspective Therapeutics, Inc.Perspective Therapeutics, Inc., is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.

The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.

Media and Investor Relations Contacts:

Perspective Therapeutics IR:
Annie Cheng
ir@perspectivetherapeutics.com

Russo Partners, LLC
Nic Johnson
PerspectiveIR@russopr.com